Editas Medicine Banner Image

Editas Medicine

  • Ticker EDIT
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Editas Medicine Logo Image
  • 51-200 Employees
  • Based in Cambridge, Massachusetts
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomicMore medicines for a broad class of diseases.
4.7 / 5.0 (134)

Editas Medicine reports have an aggregate usefulness score of 4.7 based on 134 reviews.

Editas Medicine

Most Recent Annual Report

Editas Medicine
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Editas Medicine Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!